Kamada (KMDA) Q1 2026 Earnings Transcript

Kamada reported Q1 revenue of $42.5 million, up 3%, with net income of $4.1 million and adjusted EBITDA of $11.6 million, while reaffirming full-year 2026 guidance of $200 million-$205 million revenue and $50 million-$53 million adjusted EBITDA. Gross margin fell to 42% from 47% due to product and market mix, partly offset by lower R&D after the InnovAATe trial ended. Management highlighted upcoming biosimilar launches, FDA-approved plasma center expansion, and a $0.25 per-share dividend as key growth and capital-return drivers.

Analysis

KMDA’s setup is less about the quarter itself and more about the shape of the next two inflection points: first, the Q2 catch-up from the delayed shipment, and second, the back-half revenue ramp from plasma monetization and biosimilar launches. The market should not overreact to the margin compression because the gross margin swing looks mix-driven rather than structurally broken; the bigger tell is that management is still comfortable holding EBITDA guidance while stepping up commercial spend, which implies operating leverage is being reserved for later in the year.

The deeper second-order effect is vertical integration. Once Houston and San Antonio begin selling source plasma, the company gets a dual benefit: external revenue from plasma sales and lower effective cost and supply risk for its own specialty products. That matters more than the headline revenue contribution because it can quietly improve resilience and margin stability over 2027-2028, especially if donor collection ramps without major capex surprises.

The market may also be underestimating how much of the growth story is now self-reinforcing. KEDRAB’s committed demand gives management a de-risked base, while CYTOGAM and the biosimilar portfolio are essentially option value on commercialization execution; if even one or two of those programs inflect, the dividend policy becomes an accelerator for multiple expansion rather than a drag on reinvestment. The key contrarian risk is that investors may be paying for a steady compounder while the real outcome is still a lumpy execution story with timing risk around regulatory approvals, launch uptake, and plasma ramp timing.

Key Decisions for Investors

• Long KMDA on a 3-6 month horizon into the expected Q2 revenue catch-up and plasma monetization start; target a re-rating if management proves the back-half ramp without another margin step-down.
• Use call spreads in KMDA rather than outright stock if liquidity allows: buy the 6-9 month upside to capture the second-half operating leverage while capping downside from launch timing slippage.
• Pair trade: long KMDA / short a slower-growth plasma-derived or specialty pharma peer with less visibility on new capacity ramp, to isolate execution-driven upside versus pure market beta.
• If already long, trim on any sharp rally before the next catalyst and re-add on confirmation of source-plasma sales commencement; the cleanest entry is after evidence, not before it.
• Monitor KMDA for a 1-2 quarter lag in CYTOGAM and biosimilar traction; if launches disappoint, the stock likely reverts to a dividend-plus-commodity-like multiple rather than a growth multiple.